Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Apr;21(4):645-57.
doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.

Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

Fergus J Couch  1 , Mia M Gaudet, Antonis C Antoniou, Susan J Ramus, Karoline B Kuchenbaecker, Penny Soucy, Jonathan Beesley, Xiaoqing Chen, Xianshu Wang, Tomas Kirchhoff, Lesley McGuffog, Daniel Barrowdale, Andrew Lee, Sue Healey, Olga M Sinilnikova, Irene L Andrulis; OCGN; Hilmi Ozcelik, Anna Marie Mulligan, Mads Thomassen, Anne-Marie Gerdes, Uffe Birk Jensen, Anne-Bine Skytte, Torben A Kruse, Maria A Caligo, Anna von Wachenfeldt, Gisela Barbany-Bustinza, Niklas Loman, Maria Soller, Hans Ehrencrona, Per Karlsson; SWE-BRCA; Katherine L Nathanson, Timothy R Rebbeck, Susan M Domchek, Ania Jakubowska, Jan Lubinski, Katarzyna Jaworska, Katarzyna Durda, Elzbieta Zlowocka, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Cezary Cybulski, Bohdan Górski, Ana Osorio, Mercedes Durán, María Isabel Tejada, Javier Benitez, Ute Hamann, Frans B L Hogervorst; HEBON; Theo A van Os, Flora E van Leeuwen, Hanne E J Meijers-Heijboer, Juul Wijnen, Marinus J Blok, Marleen Kets, Maartje J Hooning, Rogier A Oldenburg, Margreet G E M Ausems, Susan Peock, Debra Frost, Steve D Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Chris Jacobs, Rosalind A Eeles, Julian Adlard, Rosemarie Davidson, Diana M Eccles, Trevor Cole, Jackie Cook, Joan Paterson, Carole Brewer, Fiona Douglas, Shirley V Hodgson, Patrick J Morrison, Lisa Walker, Mary E Porteous, M John Kennedy, Lucy E Side; EMBRACE; Betsy Bove, Andrew K Godwin, Dominique Stoppa-Lyonnet; GEMO Study Collaborators; Marion Fassy-Colcombet, Laurent Castera, François Cornelis, Sylvie Mazoyer, Mélanie Léoné, Nadia Boutry-Kryza, Brigitte Bressac-de Paillerets, Olivier Caron, Pascal Pujol, Isabelle Coupier, Capucine Delnatte, Linda Akloul, Henry T Lynch, Carrie L Snyder, Saundra S Buys, Mary B Daly, Marybeth Terry, Wendy K Chung, Esther M John, Alexander Miron, Melissa C Southey, John L Hopper, David E Goldgar, Christian F Singer, Christine Rappaport, Muy-Kheng M Tea, Anneliese Fink-Retter, Thomas V O Hansen, Finn C Nielsen, Aðalgeir Arason, Joseph Vijai, Sohela Shah, Kara Sarrel, Mark E Robson, Marion Piedmonte, Kelly Phillips, Jack Basil, Wendy S Rubinstein, John Boggess, Katie Wakeley, Amanda Ewart-Toland, Marco Montagna, Simona Agata, Evgeny N Imyanitov, Claudine Isaacs, Ramunas Janavicius, Conxi Lazaro, Ignacio Blanco, Lidia Feliubadalo, Joan Brunet, Simon A Gayther, Paul P D Pharoah, Kunle O Odunsi, Beth Y Karlan, Christine S Walsh, Edith Olah, Soo Hwang Teo, Patricia A Ganz, Mary S Beattie, Elizabeth J van Rensburg, Cecelia M Dorfling, Orland Diez, Ava Kwong, Rita K Schmutzler, Barbara Wappenschmidt, Christoph Engel, Alfons Meindl, Nina Ditsch, Norbert Arnold, Simone Heidemann, Dieter Niederacher, Sabine Preisler-Adams, Dorothea Gadzicki, Raymonda Varon-Mateeva, Helmut Deissler, Andrea Gehrig, Christian Sutter, Karin Kast, Britta Fiebig, Wolfram Heinritz, Trinidad Caldes, Miguel de la Hoya, Taru A Muranen, Heli Nevanlinna, Marc D Tischkowitz, Amanda B Spurdle, Susan L Neuhausen, Yuan Chun Ding, Noralane M Lindor, Zachary Fredericksen, V Shane Pankratz, Paolo Peterlongo, Siranoush Manoukian, Bernard Peissel, Daniela Zaffaroni, Monica Barile, Loris Bernard, Alessandra Viel, Giuseppe Giannini, Liliana Varesco, Paolo Radice, Mark H Greene, Phuong L Mai, Douglas F Easton, Georgia Chenevix-Trench; kConFab investigators; Kenneth Offit, Jacques Simard; Consortium of Investigators of Modifiers of BRCA1/2
Affiliations
Multicenter Study

Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers

Fergus J Couch et al. Cancer Epidemiol Biomarkers Prev. 2012 Apr.

Abstract

Background: Genome-wide association studies (GWAS) identified variants at 19p13.1 and ZNF365 (10q21.2) as risk factors for breast cancer among BRCA1 and BRCA2 mutation carriers, respectively. We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Methods: Genotyping data for 12,599 BRCA1 and 7,132 BRCA2 mutation carriers from 40 studies were combined.

Results: We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for BRCA1 mutation carriers [HR, 1.17; 95% confidence interval (CI), 1.07-1.27; P = 7.42 × 10(-4)] and between rs16917302 at ZNF365 (HR, 0.84; 95% CI, 0.73-0.97; P = 0.017) but not rs311499 at 20q13.3 (HR, 1.11; 95% CI, 0.94-1.31; P = 0.22) and breast cancer risk for BRCA2 mutation carriers. Analyses based on tumor histopathology showed that 19p13 variants were predominantly associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2 mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast cancer for both BRCA1 and BRCA2 mutation carriers. We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1 (HR, 1.16; 95% CI, 1.05-1.29; P = 3.8 × 10(-4)) and BRCA2 mutation carriers (HR, 1.30; 95% CI, 1.10-1.52; P = 1.8 × 10(-3)).

Conclusions: 19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes of breast cancer among BRCA1 and BRCA2 mutation carriers.

Impact: These findings can lead to an improved understanding of tumor development and may prove useful for breast and ovarian cancer risk prediction for BRCA1 and BRCA2 mutation carriers.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. No potential conflicts of interest are disclosed.

Figures

Figure 1
Figure 1. Forest plots of the associations by country of residence of BRCA1 and BRCA2 mutation carriers with breast cancer risk overall
(A–C) Squares indicate the country specific per-allele HR estimates for SNPs (A) rs8170 for BRCA1 mutation carriers, (B) rs67397200 for BRCA1 mutation carriers and (C) rs16917302 for BRCA2 mutation carriers. The area of the square is proportional to the inverse of the variance of the estimate. Horizontal lines indicate 95% Confidence Intervals (CIs).
Figure 1
Figure 1. Forest plots of the associations by country of residence of BRCA1 and BRCA2 mutation carriers with breast cancer risk overall
(A–C) Squares indicate the country specific per-allele HR estimates for SNPs (A) rs8170 for BRCA1 mutation carriers, (B) rs67397200 for BRCA1 mutation carriers and (C) rs16917302 for BRCA2 mutation carriers. The area of the square is proportional to the inverse of the variance of the estimate. Horizontal lines indicate 95% Confidence Intervals (CIs).
Figure 1
Figure 1. Forest plots of the associations by country of residence of BRCA1 and BRCA2 mutation carriers with breast cancer risk overall
(A–C) Squares indicate the country specific per-allele HR estimates for SNPs (A) rs8170 for BRCA1 mutation carriers, (B) rs67397200 for BRCA1 mutation carriers and (C) rs16917302 for BRCA2 mutation carriers. The area of the square is proportional to the inverse of the variance of the estimate. Horizontal lines indicate 95% Confidence Intervals (CIs).
See this image and copyright information in PMC

References

    1. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70:9742–9754. - PMC - PubMed
    1. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2011;20:3304–3321. - PMC - PubMed
    1. Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, et al. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2010;19:2859–2868. - PMC - PubMed
    1. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20:3289–3303. - PMC - PubMed
    1. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010;42:885–892. - PMC - PubMed

Publication types

MeSH terms

Grants and funding